Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of SCLC January 28, 2025
FDA Clears 225Ac-Satoreotide Ph 1/2 Clinical Study in Patients with SCLC or Merkel Cell Carcinoma January 21, 2025
Asher Bio Announces Clinical Trial Collaboration & Supply Agreement on Etakafusp Alfa (AB248) in Combination with Bispecific T-cell Engager in SCLC Patients January 15, 2025
FDA clears IND for Ph 1/2 clinical trial of REC-4539 in SCLC and MHRA clears IND for Ph 1 clinical trial of REC-3565 for B-cell malignancies January 15, 2025
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849 Targeting SCLC and NET Solid Tumors December 31, 2024
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for 2L Treatment of ES-SCLC December 26, 2024
ZL-1310 Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage SCLC October 29, 2024
Positive and Statistically Significant OS and PFS Results for Zepzelca® (lurbinectedin) & Atezolizumab Combo in 1L Maintenance Therapy for ES-SCLC October 22, 2024
Ifinatamab Deruxtecan Continues to Demonstrate Promising ORR in Patients with Extensive-Stage SCLC in IDeate-Lung01 Ph 2 Trial September 10, 2024
FDA grants Breakthrough Therapy Designation to GSK5764227 for R/R extensive-stage SCLC August 27, 2024
Imfinzi granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage SCLC in the US August 22, 2024
Ph 3 KeyVibe-008 Trial of Vibostolimab + Pembrolizumab in Patients With Extensive-Stage SCLC to be discontinued as per IDMC recommendations August 13, 2024
IDeate-Lung02 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed SCLC August 7, 2024
FDA grants Fast Track Designation for ABD-147 for the Treatment of Patients with Extensive-stage SCLC July 1, 2024
FDA approves Imdelltra™ (tarlatamab-dlle) for The Treatment Of Extensive-Stage Small Cell Lung Cancer May 21, 2024
Imfinzi significantly improved OS and PFS for patients with limited-stage SCLC in ADRIATIC Ph 3 trial April 8, 2024
European Commission approves Tecentriq SC, the EU’s first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types January 23, 2024
